Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
US Department of Justice
Healthtrust
Chubb
Teva
Accenture
Julphar
Moodys
Baxter

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,277,384

« Back to Dashboard

Which drugs does patent 6,277,384 protect, and when does it expire?

Patent 6,277,384 protects TARGINIQ and is included in one NDA.

This patent has forty-six patent family members in twenty-seven countries.
Summary for Patent: 6,277,384
Title: Opioid agonist/antagonist combinations
Abstract:The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, "aversive" experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
Inventor(s): Kaiko; Robert F. (Weston, CT), Colucci; Robert D. (Newtown, CT)
Assignee: Euro-Celtique S.A. (Luxembourg)
Application Number:09/218,662
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Delivery; Use; Formulation;

Drugs Protected by US Patent 6,277,384

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-001 Jul 23, 2014 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-002 Jul 23, 2014 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-003 Jul 23, 2014 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,277,384

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,419,686 Opioid agonist/antagonist combinations ➤ Subscribe
8,936,808 Opioid agonist/opioid antagonist/acetaminophen combinations ➤ Subscribe
6,375,957 Opioid agonist/opioid antagonist/acetaminophen combinations ➤ Subscribe
8,673,355 Opioid agonist/antagonist combinations ➤ Subscribe
9,205,082 Opioid agonist/antagonist combinations ➤ Subscribe
9,474,750 Opioid agonist/opioid antagonist/acetaminophen combinations ➤ Subscribe
6,475,494 Opioid agonist/antagonist combinations ➤ Subscribe
7,749,542 Opioid agonist/antagonist combinations ➤ Subscribe
7,172,767 Opioid agonist / antagonist combinations ➤ Subscribe
6,696,066 Opioid agonist/antagonist combinations ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,277,384

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Turkey 200001942 ➤ Subscribe
Slovenia 2266564 ➤ Subscribe
Slovenia 1685839 ➤ Subscribe
Slovenia 1041987 ➤ Subscribe
Russian Federation 2241458 ➤ Subscribe
Serbia 50070 ➤ Subscribe
Yugoslavia 39400 ➤ Subscribe
Portugal 1685839 ➤ Subscribe
Portugal 2266564 ➤ Subscribe
Portugal 1041987 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Novartis
Baxter
McKinsey
QuintilesIMS
Teva
Fuji
Express Scripts
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot